Table 1.
Characteristics and fasting lipid/lipoprotein profile of the evaluated patients with type 2 diabetes.
| Placebo (n = 10) | n-3 PUFA (n = 10) | %Δ | P | |
|---|---|---|---|---|
| Body weight, kg | 106.1 ± 19.5 | 105.8 ± 21.0 | −0.3 | 0.7 |
| Body mass index, kg/m2 | 34.1 ± 5.5 | 34.1 ± 6.1 | — | 0.7 |
| Serum | ||||
| Cholesterol, mmol/L | 4.68 ± 0.80 | 4.96 ± 0.58 | +6.0 | 0.05 |
| Triglycerides, mmol/L | 2.58 ± 1.12 | 2.33 ± 0.94 | −9.7 | 0.05 |
| LDL-cholesterol, mmol/L | 2.55 ± 0.72 | 2.86 ± 0.47 | +12.2 | 0.04 |
| HDL-cholesterol, mmol/L | 0.95 ± 0.17 | 1.03 ± 0.20 | +8.4 | 0.007 |
| Apolipoprotein B, g/L | 1.00 ± 0.19 | 1.03 ± 0.11 | +3.0 | 0.4 |
| Apolipoprotein AI, g/L | 1.12 ± 0.18 | 1.15 ± 0.14 | +2.6 | 0.4 |
| Glucose homeostasis | ||||
| Glucose, mmol/L | 7.3 ± 1.6 | 8.1 ± 2.2 | +11.0 | 0.3 |
| Insulin, ρmol/L | 147 ± 86 | 164 ± 109 | +11.9 | 0.6 |
| HbA1c | 0.070 ± 0.010 | 0.072 ± 0.011 | +2.9 | 0.1 |
PUFA: polyunsaturated fatty acid.
Mean ± SD; % represents the percentage of difference between the two intervention phases.